Literature DB >> 27338198

A 1-day visit in a severe asthma centre: effect on asthma control, quality of life and healthcare use.

Akke-Nynke van der Meer1, Henk Pasma2, Wilma Kempenaar-Okkema2, Jo-Anneke Pelinck3, Myrte Schutten4, Huib Storm5, Anneke Ten Brinke2.   

Abstract

Patients with uncontrolled asthma report ongoing symptoms, poor quality-of-life and extensive healthcare use (HCU) and might benefit from management by a specialised severe asthma team. It is unknown whether a one-time evaluation by asthma experts, without long-term supervision by a specialised team, provides favourable outcomes. We evaluated asthma control (Asthma Control Questionnaire; ACQ), quality-of-life (Asthma-related Quality of Life Questionnaire; AQLQ) and HCU before and 1 year after a 1-day visit programme in a severe asthma centre, including a multidisciplinary assessment resulting in a personalised management plan to be implemented by patients own pulmonologists.40 uncontrolled asthma patients completed questionnaires (ACQ, AQLQ, HCU) at baseline, and 6 and 12 months follow-up.ACQ improved from 2.6 (interquartile range 1.7-3.2) to 1.8 (1.2-3.2) (p=0.003) and AQLQ from 4.8 (4.0-5.2) to 5.3 (4.4-6.0) (p<0.001). We found a reduction in patients with ≥2 exacerbations (95% versus 17%; p<0.001), ≥1 emergency room visit (78% versus 37%; p<0.001) and ≥1 hospitalisation (47% versus 10%; p=0.001).Evaluation of uncontrolled asthma patients in a 1-day visit programme in a severe asthma centre resulted in significant improvements in asthma control, quality-of-life and healthcare use after 1 year. This 1-day visit approach seems beneficial for uncontrolled asthma patients and might reduce their dependence on expensive treatment modalities and long-term management in specialised centres.
Copyright ©ERS 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27338198     DOI: 10.1183/13993003.00220-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  6 in total

1.  Preview of highlighted presentations from the European Respiratory Society' clinical assembly.

Authors:  Nicolas Kahn; Lowie E G W Vanfleteren; Georgios Kaltsakas; Vasileios Andrianopoulos; Daniela Gompelmann; Corina de Jong; Felix J F Herth
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 2.  Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand.

Authors:  John Blakey; Li Ping Chung; Vanessa M McDonald; Laurence Ruane; John Gornall; Chris Barton; Sinthia Bosnic-Anticevich; John Harrington; Mark Hew; Anne E Holland; Trudy Hopkins; Lata Jayaram; Helen Reddel; John W Upham; Peter G Gibson; Philip Bardin
Journal:  Respirology       Date:  2021-09-29       Impact factor: 6.175

Review 3.  Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults.

Authors:  Celeste Porsbjerg; Charlotte Ulrik; Tina Skjold; Vibeke Backer; Birger Laerum; Sverre Lehman; Crister Janson; Thomas Sandstrøm; Leif Bjermer; Barbro Dahlen; Bo Lundbäck; Dora Ludviksdottir; Unnur Björnsdóttir; Alan Altraja; Lauri Lehtimäki; Paula Kauppi; Jussi Karjalainen; Hannu Kankaanranta
Journal:  Eur Clin Respir J       Date:  2018-03-06

4.  Roadmap to improve regional care for patients with severe asthma.

Authors:  J P M van der Valk; J H Kappen; J S J A van Campen; G Epping; J M A M Retera; D de Bondt; F Suwandy; M Tolboom; J C C M In't Veen; G J Braunstahl
Journal:  Clin Transl Allergy       Date:  2021-12       Impact factor: 5.871

Review 5.  Rational oral corticosteroid use in adult severe asthma: A narrative review.

Authors:  Li Ping Chung; John W Upham; Philip G Bardin; Mark Hew
Journal:  Respirology       Date:  2019-11-12       Impact factor: 6.424

6.  Alpine altitude climate treatment for severe and uncontrolled asthma: An EAACI position paper.

Authors:  Karin B Fieten; Marieke T Drijver-Messelink; Annalisa Cogo; Denis Charpin; Milena Sokolowska; Ioana Agache; Luís Manuel Taborda-Barata; Ibon Eguiluz-Gracia; Gerrit J Braunstahl; Sven F Seys; Maarten van den Berge; Konrad E Bloch; Silvia Ulrich; Carlos Cardoso-Vigueros; Jasper H Kappen; Anneke Ten Brinke; Markus Koch; Claudia Traidl-Hoffmann; Pedro da Mata; David J Prins; Suzanne G M A Pasmans; Sarah Bendien; Maia Rukhadze; Mohamed H Shamji; Mariana Couto; Hanneke Oude Elberink; Diego G Peroni; Giorgio Piacentini; Els J M Weersink; Matteo Bonini; Lucia H M Rijssenbeek-Nouwens; Cezmi A Akdis
Journal:  Allergy       Date:  2022-02-15       Impact factor: 14.710

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.